Genentech: PD-L1 Metastatic Non-small Cell Lung Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight | Gilead Sciences, BieGene, GlaxoSmithKline, Arcus Biosciences/ Gilead Sciences, Hoffmann-La Roche/Genentech,

DelveInsight's "PD-L1 Metastatic Non-small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032" Report delivers an in-depth understanding of the PD-L1 Metastatic Non-small Cell Lung Cancer, historical and forecasted epidemiology as well as the PD-L1 Metastatic Non-small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover which therapies are expected to grab the PD-L1 Metastatic Non-small Cell Lung Cancer Market Share @ PD-L1 Metastatic Non-small Cell Lung Cancer Market Outlook- https://www.delveinsight.com/sample-request/pd-l1-mnsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways from the PD-L1 Metastatic Non-small Cell Lung Cancer Market Report • The total number of incident cases of NSCLC in the 7MM was nearly 526,800 cases in 2022 and are projected to increase during the forecasted period. • The total number of incident cases of NSCLC in the United States was nearly 201,200 in 2022. • The total number of cases in United states for PD-L1 NSCLC was estimated to be nearly 100,600 cases in 2022, which is expected to show positive growth by 2032. • The total number of cases in EU4 and the UK for PD-L1 NSCLC was estimated to be nearly 102,200 cases in 2022. • Among EU4 and the UK, the highest number of cases for PD-L1 NSCLC was found in Germany which was estimated to nearly 27,800 cases in 2022. • The total number of cases in Japan for PD-L1 NSCLC was estimated to be nearly 59,900 cases in 2022 • The increase in PD-L1 Metastatic Non-small Cell Lung Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. • As per DelveInsight analysis, the PD-L1 Metastatic Non-small Cell Lung Cancer Market is anticipated to witness growth at a considerable CAGR. • The leading PD-L1 Metastatic Non-small Cell Lung Cancer Companies such as Daiichi Sankyo/AstraZeneca, Gilead Sciences, BieGene, GlaxoSmithKline, Arcus Biosciences/ Gilead Sciences, Hoffmann-La Roche/Genentech, GlaxoSmithKline, Jiangsu HengRui Medicine, EQRx/CStone, AstraZeneca, Regeneron Pharmaceuticals, Shanghai Henlius Biotech, GlaxoSmithKline, OncoC4/BioNTech and others. • Promising PD-L1 Metastatic Non-small Cell Lung Cancer Pipeline Therapies such as KEYTRUDA (Pembrolizumab), OPDIVO (nivolumab), Sugemalimab (CS1001), Datopotamab Deruxtecan, and others. Stay ahead in the PD-L1 Metastatic Non-small Cell Lung Cancer Therapeutics Market with DelveInsight's Strategic Report @ PD-L1 Metastatic Non-small Cell Lung Cancer Market Outlook- https://www.delveinsight.com/sample-request/pd-l1-mnsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr PD-L1 Metastatic Non-small Cell Lung Cancer Epidemiology Segmentation in the 7MM The epidemiology section of PD-L1 Metastatic Non-small Cell Lung Cancer offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions. • Total PD-L1 Metastatic NSCLC Incident Cases • PD-L1 Metastatic NSCLC Gender-specific Cases • PD-L1 Metastatic NSCLC Age-specific Cases • Total PD-L1 Metastatic NSCLC Incident Cases • Total PD-L1 Metastatic NSCLC Incident Cases by Stage • Total PD-L1 Metastatic NSCLC Cases by Genetic Mutations/Biomarkers Download the report to understand which factors are driving PD-L1 Metastatic Non-small Cell Lung Cancer Epidemiology trends @ PD-L1 Metastatic Non-small Cell Lung Cancer Prevalence- https://www.delveinsight.com/sample-request/pd-l1-mnsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr PD-L1 Metastatic Non-small Cell Lung Cancer Marketed Drugs • KEYTRUDA (Pembrolizumab): MSD Keytruda, also known as Pembrolizumab, is a PD-1 blocking antibody. It is mainly used for advanced cancers that have spread to other body parts or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high protein levels known as PD-L1. This drug is also used to help prevent cancer from coming back after patients had surgery. It is approved for multiple types of cancer. In NSCLC, it is in combination with pemetrexed and platinum chemotherapy as first-line treatment of patients with metastatic non squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. Combining with carboplatin and either paclitaxel or paclitaxel protein-bound as first-line treatment of patients with metastatic squamous NSCLC. • OPDIVO (nivolumab): Bristol-Myers Squibb/Ono Pharmaceutical Opdivo (Nivolumab) by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. It is a prescription medicine used to treat people with unresectable or metastatic melanoma, metastatic NSCLC, SCLC, advanced renal cell carcinoma, classical Hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer and hepatocellular carcinoma PD-L1 Metastatic Non-small Cell Lung Cancer Emerging Drugs • Sugemalimab (CS1001): EQRx/CStone Sugemalimab (CS1001) is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. Authorized by the US-based Ligand Corporation, sugemalimab is developed by the OmniRat transgenic animal platform, which can generate fully human antibodies in one stop. As a fully human, full-length anti-PD-L1 monoclonal antibody, sugemalimab mirrors the natural G-type immunoglobulin 4 (IgG4) human antibody, which can reduce the risk of immunogenicity and potential toxicities in patients, a unique advantage over similar drugs. • Datopotamab Deruxtecan: Daiichi Sankyo/AstraZeneca Datopotamab Deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Designed using Daiichi Sankyo's proprietary DXd ADC technology, Datopotamab Deruxtecan is one of five lead ADCs in the oncology pipeline of Daiichi Sankyo and one of the most advanced programs in AstraZeneca's ADC scientific platform. In NSCLC, the TROPION-Lung07, TROPION-Lung08, and AVANZAR Phase III trials are evaluating Datopotamab Deruxtecan and immune checkpoint inhibitor combinations as potential first-line treatment options for patients with advanced or metastatic disease, a strategy informed by the results of two early trials. AstraZeneca is also researching a potential diagnostic test to help identify patients most likely to benefit from treatment with Datopotamab Deruxtecan. To learn more about PD-L1 Metastatic Non-small Cell Lung Cancer treatment guidelines, visit @ PD-L1 Metastatic Non-small Cell Lung Cancer Treatment Market Landscape- https://www.delveinsight.com/sample-request/pd-l1-mnsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr PD-L1 Metastatic Non-small Cell Lung Cancer Market Outlook Till the last decade, chemotherapy was used as the standard of care in the advanced and metastatic stages until the first ICI 'KEYTRUDA (Pembrolizumab)' got approved in 2015 as a second-line treatment option for such advanced patients; a similar path was followed by TECENTRIQ (Atezolizumab) who entered the market in 2016. These therapies entered the first-line domain after 2016 and expanded their labels by expanding the targetable pool. Recently, in 2020, OPDIVO (nivolumab) + ipilimumab was approved as a 1L treatment for patients with metastatic NSCLC. Chinese companies are trying to enter the US and EU market, especially the EU Market, where Tislelizumab and Sugemalimab currently under review. Tislelizumab's and Sugemalimab's developers have abandoned their filing plans in the United States. In the EU, these companies are trying for approval based on Chinese trials. The new area of development in NSCLC includes TROP-2-directed ADC's, T cell immunoreceptors with Ig and ITIM domains (TIGIT), and LAG-3 inhibitors majorly being targeted by the researchers, and the big companies such as AstraZeneca, Daiichi Sankyo, Beigene, Hoffmann-La Roche, Gilead Sciences, and others have their potential candidates in late stages of development. PD-L1 Metastatic Non-small Cell Lung Cancer Drugs Uptake The drug chapter of the PD-L1 Metastatic Non-small Cell Lung Cancer report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to PD-L1 Metastatic Non-small Cell Lung Cancer. Major PD-L1 Metastatic Non-small Cell Lung Cancer Companies Daiichi Sankyo/AstraZeneca, Gilead Sciences, BieGene, GlaxoSmithKline, Arcus Biosciences/ Gilead Sciences, Hoffmann-La Roche/Genentech, GlaxoSmithKline, Jiangsu HengRui Medicine, EQRx/CStone, AstraZeneca, Regeneron Pharmaceuticals, Shanghai Henlius Biotech, GlaxoSmithKline, OncoC4/BioNTech and others. Learn more about the FDA-approved drugs for PD-L1 Metastatic Non-small Cell Lung Cancer @ Drugs for PD-L1 Metastatic Non-small Cell Lung Cancer Treatment- https://www.delveinsight.com/sample-request/pd-l1-mnsclc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Scope of the PD-L1 Metastatic Non-small Cell Lung Cancer Market Report • Coverage- 7MM • Study Period- 2019-2032 • PD-L1 Metastatic Non-small Cell Lung Cancer Companies- • PD-L1 Metastatic Non-small Cell Lung Cancer Pipeline Therapies- KEYTRUDA (Pembrolizumab), OPDIVO (nivolumab), Sugemalimab (CS1001)